Market Place
Sourcing Support
Werewolf Therapeutics To Participate In 7th Evercore ISI HealthCONx
20 Nov 2024 //
GLOBENEWSWIRE
Werewolf Therapeutics Reports Q3 2024 Financial Results & Update
07 Nov 2024 //
GLOBENEWSWIRE
Werewolf Therapeutics Presents Data at SITC 2024 & Q3 Results
07 Nov 2024 //
GLOBENEWSWIRE
Werewolf Therapeutics Announces New IL-10 INDUKINE™ Candidate
31 Oct 2024 //
GLOBENEWSWIRE
Werewolf Therapeutics To Present Posters At SITC Meeting
04 Oct 2024 //
GLOBENEWSWIRE
Werewolf Therapeutics to Attend H.C. Wainwright Global Investment Conference
03 Sep 2024 //
GLOBENEWSWIRE
Werewolf Therapeutics Reports Q2 2024 Results And Business Update
08 Aug 2024 //
GLOBENEWSWIRE
Werewolf Therapeutics Highlights Safety and Efficacy Data from WTX-330 Trial
25 Jun 2024 //
GLOBENEWSWIRE
Werewolf`s WTX-124 Mono/Combo Data In Solid Tumors At ASCO
01 Jun 2024 //
GLOBENEWSWIRE
Werewolf At Jefferies Global Healthcare Conference
30 May 2024 //
GLOBENEWSWIRE
Werewolf Wtx-124 Updated Data: Phase 1/1b Mono/Pembro Combo Solids
23 May 2024 //
GLOBENEWSWIRE
Werewolf Reports Q1 2024 Results, Business Updates
03 May 2024 //
GLOBENEWSWIRE
Werewolf`s WTX-124 Abstract at ASCO 2024 Annual Meeting
24 Apr 2024 //
GLOBENEWSWIRE
Werewolf Presents Preclinical Data On IL-10 INDUKINEs For IBD At AAI
23 Apr 2024 //
GLOBENEWSWIRE
Werewolf Therapeutics Presents Results of WTX-518 & WTX-712 at AACR 2024
05 Apr 2024 //
GLOBENEWSWIRE
Werewolf to Present Data Demonstrating Utility for PREDATOR at AAI Meeting
04 Apr 2024 //
GLOBENEWSWIRE
Werewolf Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results
07 Mar 2024 //
GLOBENEWSWIRE
Werewolf to Present at the 2024 Leerink Partners Global Biopharma Conference
06 Mar 2024 //
GLOBENEWSWIRE
Werewolf Announces Upcoming Presentations at AACR Annual Meeting 2024
05 Mar 2024 //
GLOBENEWSWIRE
Werewolf Therapeutics Highlights 2024 Strategic Outlook
08 Jan 2024 //
GLOBENEWSWIRE
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
04 Jan 2024 //
GLOBENEWSWIRE
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
22 Nov 2023 //
GLOBENEWSWIRE
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
Werewolf Therapeutics Presents Monotherapy Data from Phase 1/1b for WTX-124
03 Nov 2023 //
GLOBENEWSWIRE
Werewolf Therapeutics to Present Clinical and Preclinical Data at SITC
31 Oct 2023 //
GLOBENEWSWIRE
Werewolf Therapeutics Announces Upcoming Presentations at SITC
27 Sep 2023 //
GLOBENEWSWIRE
Werewolf to Host Event Highlighting IL-2 Landscape and Opportunity for WTX-124
11 Sep 2023 //
GLOBENEWSWIRE
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
05 Sep 2023 //
GLOBENEWSWIRE
Werewolf Therapeutics Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Werewolf Therapeutics to Present at the Jefferies Healthcare Conference
01 Jun 2023 //
GLOBENEWSWIRE
Werewolf Therapeutics Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Werewolf Therapeutics to Participate in May Investor Conferences
01 May 2023 //
GLOBENEWSWIRE
Werewolf Therapeutics Publishes Preclinical Data on mWTX-330
19 Apr 2023 //
GLOBENEWSWIRE
Werewolf Therapeutics 4Q & 2022 FYR and Provides Business Update
23 Mar 2023 //
GLOBENEWSWIRE
Werewolf Therapeutics Announces Presentations at AACR Annual Meeting 2023
16 Mar 2023 //
GLOBENEWSWIRE
Werewolf Announces Upcoming Presentation at AACR Annual Meeting 2023
15 Mar 2023 //
GLOBENEWSWIRE
Werewolf Therapeutics begins subject dosing in Phase I trial of WTX-330
27 Feb 2023 //
CLINICAL TRIALS ARENA
Werewolf Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330
24 Feb 2023 //
GLOBENEWSWIRE
Werewolf to Present at the SVB Securities Global Biopharma Conference
07 Feb 2023 //
GLOBENEWSWIRE
Werewolf Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™
10 Nov 2022 //
GLOBENEWSWIRE
Werewolf Therapeutics Reports 3Q 2022 Financial Results
10 Nov 2022 //
GLOBENEWSWIRE
Werewolf Therapeutics to Present Preclinical Data at Society for Immunotherapy p
07 Nov 2022 //
GLOBENEWSWIRE
Werewolf Therapeutics to Present at the H.C. Wainwright 24th Annual GIC
07 Sep 2022 //
GLOBENEWSWIRE
Werewolf doses first subject in Phase I/Ib trial of solid tumour therapy
02 Sep 2022 //
CLINICALTRIALSARENA
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1/1b
01 Sep 2022 //
GLOBENEWSWIRE
Werewolf Therapeutics Reports Q2 2022 Rusult and Provides Business Highlights
11 Aug 2022 //
GLOBENEWSWIRE
Werewolf Therapeutics to Participate in the 2022 Wedbush Virtual Conference
03 Aug 2022 //
GLOBENEWSWIRE
Werewolf Therapeutics to Participate in Fireside Chat at Jefferies Conference
06 Jun 2022 //
GLOBENEWSWIRE
Werewolf Therapeutics Reports First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
Werewolf Tx Presents Promising PC Data on INDUKINE Molecules at AACR
08 Apr 2022 //
GLOBENEWSWIRE
Jazz, Werewolf Enter Excl. Global License & Collaboration Agreement for WTX-613
07 Apr 2022 //
PRNEWSWIRE
Werewolf Tx Reports Q4 2021 and Full Year 2021 Financial Results
24 Mar 2022 //
GLOBENEWSWIRE
Werewolf Tx says Publication of Data Demonstrating the PC Efficacy of WTX-124
16 Mar 2022 //
GLOBENEWSWIRE
Werewolf Therapeutics Appoints Meeta Chatterjee, Ph.D., to itsBOD
28 Oct 2021 //
GLOBENEWSWIRE
Werewolf Therapeutics to Present Data on its INDUKINE™ Product Candidates
27 Oct 2021 //
GLOBENEWSWIRE
Werewolf Therapeutics to Present Upcoming Next-Gen Cytokine Therapeutics Summit
14 Sep 2021 //
GLOBENEWSWIRE
Werewolf Therapeutics Announces Clinical Trial Collaboration with Merck
18 Aug 2021 //
GLOBENEWSWIRE
Werewolf Therapeutics Announces Its Addition to the Russell 2000® Index
24 Jun 2021 //
GLOBENEWSWIRE
Werewolf Therapeutics Appoints Chulani Karunatilake, Ph.D. as CTO
15 Jun 2021 //
GLOBENEWSWIRE
Werewolf Therapeutics Reports First Quarter 2021 Financial Results
10 Jun 2021 //
GLOBENEWSWIRE
